Carregant...
The Subcontinental Surge
Biotech is following big pharma to India, where R&D costs are a fraction of those in the U.S. India itself is working hard to make it happen. Ultimately, this could reduce the price of biotech therapies. But what about India’s reputation for disregarding intellectual property rights?
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioCommunications LLC
2004
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3564301/ https://ncbi.nlm.nih.gov/pubmed/23393438 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|